Ipsen, Exicure to co-develop therapies for neurodegenerative diseases
Biopharmaceutical company Ipsen and Exicure have collaborated to research, develop, and commercialize novel Spherical Nucleic Acids (SNAs) as potential investigational therapies to treat Angelman syndrome and Huntington’s disease.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.